# üëè ‰æùËµñËÆ°ÁÆóÊú∫ËæÖÂä©ËçØÁâ©ËÆæËÆ°ÊäÄÊúØÊàêÂäü‰∏äÂ∏ÇÁöÑËçØÁâ©

---
## Áõ∏ÂÖ≥ÊñáÁåÆ
1. Cushman DW, Cheung HS, Sabo EF, Ondetti A. Design of Potent Competitive Inhibitors of Angiotensin-Converting Enzyme. Carboxyalkanoyl and Mercaptoalkanoyl Amino Acids. Biochemistry. 1977;16(25):5484-5491. doi:10.1021/bi00644a014.

2. Baldwin JJ, Ponticello GS, Anderson PS, et al. Thienothiopyran-2-sulfonamides: Novel Topically Active Carbonic Anhydrase Inhibitors for the Treatment of Glaucoma. J Med Chem. 1989;32(12):2510-2513. doi:10.1021/jm00132a003.

3. Roberts NA, Martin JA, Kinchington D, et al. Rational design of peptide-based HIV proteinase inhibitors. Science (80- ). 1990;248(4953):358-361. doi:10.1126/science.2183354.

4. Kempf DJ, Sham HL, Marsh KC, et al. Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy. J Med Chem. 1998;41(4):602-617. doi:10.1021/jm970636+.

5. Dorsey BD, Levin RB, McDaniel SL, et al. L-735,524: The Design of a Potent and Orally Bioavailable HIV Protease Inhibitor. J Med Chem. 1994;37(21):3443-3451. doi:10.1021/jm00047a001.

6. Silver LH. Dose-response evaluation of the ocular hypotensive effect of brinzolamide ophthalmic suspension (Azopt(¬Æ)). Surv Ophthalmol. 2000;44(SUPPL. 2):147-153. doi:10.1016/S0039-6257(99)00110-1.

7. Kaldor SW, Kalish VJ, Davies JF, et al. Viracept (nelfinavir mesylate, AG1343): A potent, orally bioavailable inhibitor of HIV-1 protease. J Med Chem. 1997;40(24):3979-3985. doi:10.1021/jm9704098.

8. Kim EE, Bakei CT, Dwyer MD, et al. Crystal Structure of HIV-1 Protease in Complex with VX-478, a Potent and Orally Bioavailable Inhibitor of the Enzyme. J Am Chem Soc. 1995;117(3):1181-1182. doi:10.1021/ja00108a056.

9. Sham HL, Kempf DJ, Molla A, et al. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother. 1998;42(12):3218-3224. http://www.ncbi.nlm.nih.gov/pubmed/9835517%5Cnhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC106025/pdf/ac003218.pdf.

10. von Itzstein M, Wu WY, Kok GB, et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature. 1993;363(6428):418-423. doi:10.1038/363418a0.

11. Kim CU, Lew W, Williams MA, et al. Structure-activity relationship studies of novel carbocyclic influenza neuraminidase inhibitors. J Med Chem. 1998;41(14):2451-2460. doi:10.1021/jm980162u.

12. Druker BJ, Lydon NB. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest. 2000;105(1):3-7. doi:10.1172/JCI9083.

13. Zimmermann J, Buchdunger E, Mett H, Meyer T, Lydon NB, Traxler P. Phenylamino-pyrimidine (PAP) - Derivatives: A new class of potent and highly selective PDGF-Receptor autophosphorylation inhibitors. Bioorganic Med Chem Lett. 1996;6(11):1221-1226. doi:10.1016/0960-894X(96)00197-7.

14. Robinson BS, Riccardi K a, Gong YF, et al. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob Agents Chemother. 2000;44(8):2093-2099. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=90019&tool=pmcentrez&rendertype=abstract.

15. Becker S, Thornton L. Fosamprenavir: advancing HIV protease inhibitor treatment options. Expert Opin Pharmacother. 2004;5(9):1995-2005. doi:10.1517/14656566.5.9.1995.

16. Pollack VA, Savage DM, Baker DA, et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther. 1999;291(0022-3565 (Print)):739-748.

17. Gustafsson D, Nystr√∂m JE, Carlsson S, et al. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: Intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res. 2001;101(3):171-181. doi:10.1016/S0049-3848(00)00399-6.

18. Wilhelm SM, Carter C, Tang LY, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64(19):7099-7109. doi:10.1158/0008-5472.CAN-04-1443.

19. Turner SR, Strohbach JW, Tommasi RA, et al. Tipranavir (PNU-140690): A potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class. J Med Chem. 1998;41(18):3467-3476. doi:10.1021/jm9802158.

20. Kang KK, Yu JY, Yoo M, Kwon JW. The effect of DA-8159, a novel PDE5 inhibitor, on erectile function in the rat model of hypercholesterolemic erectile dysfunction. Int J Impot Res. 2005;17(5):409-416. doi:10.1038/sj.ijir.3901331.

21. Mendel DB, Laird AD, Xin X, et al. In Vivo Antitumor Activity of SU11248, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial Growth Factor and Platelet-derived Growth Factor Receptors. Clin Cancer Res. 2003;9(1):327 LP-337. http://clincancerres.aacrjournals.org/content/9/1/327.abstract.

22. Ghosh AK, Dawson ZL, Mitsuya H. Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV. Bioorganic Med Chem. 2007;15(24):7576-7580. doi:10.1016/j.bmc.2007.09.010.

23. Kelly WK, O‚ÄôConnor OA, Krug LM, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol. 2005;23(17):3923-3931. doi:10.1200/JCO.2005.14.167.

24. Lombardo LJ, Lee FY, Chen P, et al. Discovery of N -(2-Chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a Dual Src/Abl Kinase Inhibitor with Potent Antitumor Activity in Preclinical Assays. J Med Chem. 2004;47(27):6658-6661. doi:10.1021/jm049486a.

25. Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005;7(2):129-141. doi:10.1016/j.ccr.2005.01.007.

26. Rahuel J, Rasetti V, Maibaum J, et al. Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin. Chem Biol. 2000;7(7):493-504. doi:10.1016/S1074-5521(00)00134-4.

27. Roehrig S, Straub A, Pohlmann J, et al. Discovery of the Novel Antithrombotic Agent 5-Chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): An Oral, Direct Factor Xa Inhibitor. J Med Chem. 2005;48(19):5900-5908. doi:10.1021/jm050101d.

28. Roehrig S, Straub A, Pohlmann J, et al. Discovery of the Novel Antithrombotic Agent 5-Chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): An Oral, Direct Factor Xa Inhibitor. J Med Chem. 2005;48(19):5900-5908. doi:10.1021/jm050101d.

29. Sorbera LA, Bozzo J, Casta√±er J. Dabigatran/Dabigatran Etexilate: Prevention of DVT prevention of ischemic stroke thrombin inhibitor. Drugs Future. 2005;30(9):877-885. doi:10.1358/dof.2005.030.09.938760.

30. Das K, Clark AD, Lewi PJ, et al. Roles of Conformational and Positional Adaptability in Structure-Based Design of TMC125-R165335 (Etravirine) and Related Non-nucleoside Reverse Transcriptase Inhibitors That Are Highly Potent and Effective against Wild-Type and Drug-Resistant HIV-1 Varian. J Med Chem. 2004;47(10):2550-2560. doi:10.1021/jm030558s.

31. Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: A phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC Study 620. J Clin Oncol. 2009;27(19):3126-3132. doi:10.1200/JCO.2008.21.3223.

32. Tsai J, Lee JT, Wang W, et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci. 2008;105(8):3041-3046. doi:10.1073/pnas.0711741105.

33. Cui JJ, Tran-Dub√© M, Shen H, et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem. 2011;54(18):6342-6363. doi:10.1021/jm2007613.

34. Huang WS, Metcalf CA, Sundaramoorthi R, et al. Discovery of 3-[2-(imidazo[1,2- b ]pyridazin-3-yl)ethynyl]-4-methyl- N -{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase includin. J Med Chem. 2010;53(12):4701-4719. doi:10.1021/jm100395q.

ÂèÇËÄÉËµÑÊñôÔºö      
1. http://blog.molcalx.com.cn/2017/04/29/structure-based-drugs.html   
